AbbVie Inc. (NEO: ABBV)

Canada flag Canada · Delayed Price · Currency is CAD
25.40
-0.06 (-0.24%)
Dec 5, 2024, 12:01 PM EST
19.81%
Market Cap 436.77B
Revenue (ttm) 75.02B
Net Income (ttm) 6.86B
Shares Out n/a
EPS (ttm) 3.88
PE Ratio 63.63
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,397
Open 25.27
Previous Close 25.46
Day's Range 25.14 - 25.40
52-Week Range 21.15 - 30.02
Beta 0.62
Analysts n/a
Price Target n/a
Earnings Date Jan 31, 2025

About AbbVie

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; E... [Read more]

Sector Healthcare
Founded 2012
Employees 50,000
Stock Exchange Cboe Canada
Ticker Symbol ABBV
Full Company Profile

Financial Performance

In 2023, AbbVie's revenue was $54.32 billion, a decrease of -6.44% compared to the previous year's $58.05 billion. Earnings were $4.82 billion, a decrease of -59.09%.

Financial numbers in USD Financial Statements

News

There is no news available yet.